Written by our own Richard Wassersug appearing in UroToday.com BERKELEY, CA (UroToday.com) – Much has happened with the use of androgen deprivation to treat prostate cancer (PCa) patients since Charles Huggins first castrated a patient in order to alleviate the symptoms of advanced PCa. Back then, patients were generally elderly and symptomatic with either urethral [...]
— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]
Somastatin is a naturally occurring hormone that affects the levels of other hormone production in the body. Its most common drug use today is to treat giantism and acromegaley, a disease characterized by an over abundance of growth hormones. There is laboratory evidence that somastatin analogs such as octreotide acetate (Sandostatin/Sandoz) can affect the growth [...]
Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]
One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]